Home › Upcoming votes › Celularity Inc
Prior-year votes at Celularity Inc → 2025-2026 season, in the search
The deadline as the proxy statement states it: “Votes submitted by telephone must be received by 11:59 p.m. Eastern Time on December 29, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Annual meeting: election of one Class II director, auditor ratification, say-on-pay, say-on-pay frequency, an equity plan share increase and a financing-related share issuance.
“To approve, for purposes of Nasdaq Listing Rule 5635 and any successor rule, the issuance of shares of Class A common stock upon conversion of notes and exercise of warrants, and the other transactions and actions contemplated by the September 23, 2026 Securities Purchase Agreement and related transaction documents” Find it in the filing
“To approve an amendment to our 2021 Equity Incentive Plan to increase the number of shares of Class A common stock reserved and available for awards by 3,500,000 shares, subject to final Board confirmation” Find it in the filing
“As of the Record Date, there 1,715,541 shares remaining available for issuance under future awards to be made under our 2021 Plan.” Find it in the filing
“Steven N. Gordon, Esq. has served as our Chief Operating and Administrative Officer and a director since June 19, 2026.” Find it in the filing
“Our board of directors currently consists of five members and Dr. Hariri serves as Chairman of the board of directors.” Find it in the filing
“our board of directors recommends that future advisory votes on executive compensation be held every three years.” Find it in the filing
“Philip A. Barach has served as a member of our board of directors since September 2026.” Find it in the filing
“Our board of directors currently consists of five members” Find it in the filing
Last year’s proxy statement, page 8: “Our board of directors currently consists of six members and Dr. Hariri serves as Chairman of the board of directors.”
“Class I, which consists of Peter Diamandis, M.D., Diane Parks and Philip A. Barach, whose terms will expire at the annual meeting of stockholders to be held in 2028” Find it in the filing
Last year’s proxy statement, page 8: “Class I, which consists of Peter Diamandis, M.D., Diane Parks and Geoffrey Ling, M.D., whose terms will expire at the Annual Meeting”
“Class II, which consists of Steven N. Gordon, Esq., whose term will expire at the Annual Meeting” Find it in the filing
Last year’s proxy statement, page 8: “Class II, which consists of Vincent LeVien, whose term will expire at the annual meeting of stockholders to be held in 2026”
“increase the number of shares of Class A common stock reserved and available for awards by 3,500,000 shares” Find it in the filing
Last year’s proxy statement, page 2: “To amend our 2021 Equity Incentive Plan to increase the number of shares of common stock reserved and available for awards by 3,500,000 shares”
“Proposal Nos. 1 (director election), 3 (say-on-pay), 4 (say-on-pay frequency), 5 (equity plan amendment) and 6 (financing-related share issuance) are non-routine” Find it in the filing
Last year’s proxy statement, page 2: “YOUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR THE NOMINEE AND IN FAVOR OF THE OTHER PROPOSAL OUTLINED IN THE ACCOMPANYING PROXY STATEMENT.”
Ballot read from the proxy statement and checked. As listed in Celularity Inc’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Election of one Class II director (Steven N. Gordon, Esq.) Director election |
Board | For | 3 nominees; support 31% to 35% |
| 2 | Ratification of the appointment of EisnerAmper LLP for fiscal 2026 Auditor |
Board | For | 99.7% support |
| 3 | Advisory vote to approve executive compensation Say on pay |
Board | For | — |
| 4 | Advisory vote on the frequency of future advisory votes on executive compensation Say-on-pay frequency |
Board | 3 years | — |
| 5 | Amendment to the 2021 Equity Incentive Plan to add 3,500,000 shares | Board | For | — |
| 6 | Approval under Nasdaq Listing Rule 5635 of share issuance upon conversion of notes and exercise of warrants under the September 23, 2026 Securities Purchase Agreement | Board | For | — |
From Celularity Inc’s Form 8-K, filed December 19, 2025, for the meeting held December 19, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Peter Diamandis, M.D. | 32% | — |
| Elect Director: Diane Parks | 31% | — |
| Elect Director: Geoffrey Ling, M.D. | 35% | — |
| 2. The appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, | 99.7% | Approved |
| 3. The amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares of common stock reserved and available for awa | 83% | Not approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.